Matthew J. Piggott

Matthew J. Piggott

Auto-generated profile, based on publicly available information

Matthew J. Piggott

Chemistry, School of Molecular Sciences, University of Western Australia, Perth, WA 6009, Australia

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2006 in Amino Acids
Verified
Journal Article
Closed access
PDF file
PAP. V. Attwood
P. V. Attwood
MPM. J. Piggott
M. J. Piggott
XZX. L. Zu
X. L. Zu
PBP. G. Besant
P. G. Besant

16 December 2006 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
TKT. Ross Kelly
T. Ross Kelly
XCXiaolu Cai
Xiaolu Cai
FDFehmi Damkaci
Fehmi Damkaci
SPSreeletha B. Panicker
Sreeletha B. Panicker
BTBin Tu
Bin Tu
SJSerge Jasmin
Serge Jasmin

1 June 2010 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
TJTom H. Johnston
Tom H. Johnston
SFSusan H. Fox
Susan H. Fox
MMMatthew J. McIldowie
Matthew J. McIldowie
MPMatthew J. Piggott
Matthew J. Piggott
JBJonathan M. Brotchie
Jonathan M. Brotchie
Long-term motor complications of dopamine replacement, such as l-DOPA-induced dyskinesia (LID) and reduced quality of l-DOPA action, remain obstacles in the treatment of Parkinson's disease. Dysfunctional glutamatergic neurotransmitter systems have been observed in both the untreated parkinsonian and dyskinetic states and represent novel targets for treatment. Here, we assess the pharmacokinetic profile and corresponding pharmacodynamic effects on behavior of the orally active, selective metabotropic glutamate receptor type 5 (mGlu5) antagonist, 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) (as the hydrochloride salt) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned macaque. Six parkinsonian, MPTP-lesioned cynomolgus monkeys, with established LID, were administered acute challenges with MTEP (4.5–36 mg/kg p.o.) or vehicle, either alone or in combination with l-DOPA (33 ± 1 mg/kg p.o.). Motor activity, parkinsonian disability, and dyskinesia were assessed for a 6-h period. Plasma drug levels were assessed by liquid chromatography-tandem mass spectrometry. MTEP had no antiparkinsonian action as monotherapy. However, administration of l-DOPA in combination with MTEP (36 mg/kg) reduced peak dose LID by 96%. Moreover, although total on-time (duration for which l-DOPA exerted an antiparkinsonian effect) was not significantly reduced, MTEP (36 mg/kg) reduced the duration of on-time with disabling LID by 70% compared with that for l-DOPA alone. These effects were associated with a peak plasma concentration of 20.9 μM and an area under the curve from 0 to 24 h of 136.1 h · μM (36 mg/kg). Although total on-time was not reduced, the peak antiparkinsonian benefit of l-DOPA/MTEP (36 mg/kg) was less than that with l-DOPA alone. Selective mGlu5 inhibitors may have significant potential to ameliorate dyskinesia, but care should be taken to ensure that such effects do not come at the expense of the peak antiparkinsonian benefit of l-DOPA.

21 June 2011 in Nature Communications
Verified
Journal Article
Closed access
PDF file
GFGavin Flematti
Gavin Flematti
DMDavid J. Merritt
David J. Merritt
MPMatthew J. Piggott
Matthew J. Piggott
RTRobert Trengove
Robert Trengove
SSSteven M. Smith
Steven M. Smith
EGEmilio L. Ghisalberti
Emilio L. Ghisalberti

16 September 2019 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
MWMark C. Walkey
Mark C. Walkey
CPChandramalika R. Peiris
Chandramalika R. Peiris
Simone CiampiSimone Ciampi
Simone Ciampi
AAAlbert C. Aragonès
Albert C. Aragonès
RDRuth B. Domínguez-Espíndola
Ruth B. Domínguez-Espíndola
Nadim DarwishNadim Darwish
Nadim Darwish

11 May 2011 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
PHPhilippe Huot
Philippe Huot
TJTom H. Johnston
Tom H. Johnston
KLKatie D. Lewis
Katie D. Lewis
JKJames B. Koprich
James B. Koprich
MRM. Gabriela Reyes
M. Gabriela Reyes
JBJonathan M. Brotchie
Jonathan M. Brotchie
L-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective treatment for Parkinson's disease, but long-terml-DOPA administration is marred by the emergence of motor complications, namely, dyskinesia and a shortening of antiparkinsonian benefit (wearing-OFF). 3,4-Methylenedioxymethamphetamine (MDMA) is unique in that it exerts antidyskinetic effects and may enhance antiparkinsonian actions ofl-DOPA. MDMA is composed of two enantiomers with different pharmacological profiles; here, we describe a novel enantiospecific synthesis of the two enantiomers and expand on the previous characterization of their pharmacology.R-MDMA (rectus-MDMA) is relatively selective for 5-HT2Areceptors, whereasS-MDMA (sinister-MDMA) inhibits both serotonin (SERT) and dopamine transporters (DAT; SERT/DAT ratio of 10 to 1).R- orS-MDMA (1, 3, and 10 mg/kg, s.c.) was administered in combination withl-DOPA (15 mg/kg, s.c.) to six female common marmosets (Callithrix jacchus) rendered parkinsonian by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) administration. Motor disability, including parkinsonism and dyskinesia, and duration of antiparkinsonian benefit (ON-time) were evaluated. After the administration ofR-MDMA (3 and 10 mg/kg), the severity of peak-dose dyskinesia was decreased (by 33 and 46%, respectively;p< 0.05); although total ON-time was unchanged (∼220 min), the duration of ON-time with disabling dyskinesia was decreased by 90 min when compared tol-DOPA alone (69% reduction;p< 0.05).S-MDMA (1 mg/kg) increased the total ON-time by 88 min compared tol-DOPA alone (34% increase;p< 0.05), though dyskinesia were exacerbated. These data suggest that racemic MDMA exerts simultaneous effects, reducing dyskinesia and extending ON-time, by 5-HT2Aantagonism and SERT-selective mixed monoamine uptake inhibition, which arise from itsRandSenantiomers, respectively.